| Early outpatient treatment for Covid-19 with convalescent plasma DJ Sullivan, KA Gebo, S Shoham, EM Bloch, B Lau, AG Shenoy, ... New England Journal of Medicine 386 (18), 1700-1711, 2022 | 233 | 2022 |
| Transplant oncology: an evolving field in cancer care M Abdelrahim, A Esmail, A Abudayyeh, N Murakami, A Saharia, ... Cancers 13 (19), 4911, 2021 | 39 | 2021 |
| Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: a case report M Abdelrahim, A Esmail, G Umoru, K Westhart, A Abudayyeh, A Saharia, ... Current Oncology 29 (6), 4267-4273, 2022 | 35 | 2022 |
| Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view M Abdelrahim, A Esmail, A Saharia, A Abudayyeh, N Abdel-Wahab, ... Cancers 14 (7), 1760, 2022 | 24 | 2022 |
| Transarterial chemoembolization (TACE) plus sorafenib compared to TACE alone in transplant recipients with hepatocellular carcinoma: An institution experience M Abdelrahim, D Victor, A Esmail, S Kodali, EA Graviss, DT Nguyen, ... Cancers 14 (3), 650, 2022 | 22 | 2022 |
| Gemcitabine and cisplatin as neo-adjuvant for cholangiocarcinoma patients prior to liver transplantation: case-series M Abdelrahim, H Al-Rawi, A Esmail, J Xu, G Umoru, F Ibnshamsah, ... Current Oncology 29 (5), 3585-3594, 2022 | 17 | 2022 |
| Utility of cell-free DNA detection in transplant oncology T Reddy, A Esmail, JC Chang, RM Ghobrial, M Abdelrahim Cancers 14 (3), 743, 2022 | 17 | 2022 |
| Recent trends and advancements in the diagnosis and management of gastric cancer E Haque, A Esmail, I Muhsen, H Salah, M Abdelrahim Cancers 14 (22), 5615, 2022 | 16 | 2022 |
| Timeline of FDA-approved targeted therapy for cholangiocarcinoma SM Cho, A Esmail, A Raza, S Dacha, M Abdelrahim Cancers 14 (11), 2641, 2022 | 15 | 2022 |
| Newest therapies for cholangiocarcinoma: an updated overview of approved treatments with transplant oncology vision Y Zhang, A Esmail, V Mazzaferro, M Abdelrahim Cancers 14 (20), 5074, 2022 | 14 | 2022 |
| Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation: an institution … M Abdelrahim, A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia, ... Frontiers in Oncology 12, 908687, 2022 | 13 | 2022 |
| Pancreatic tumorigenesis: Precursors, genetic risk factors and screening M Badheeb, A Abdelrahim, A Esmail, G Umoru, K Abboud, E Al-Najjar, ... Current Oncology 29 (11), 8693-8719, 2022 | 10 | 2022 |
| Thymoquinone’s antiviral effects: it is time to be proven in the covid-19 pandemic era and its Omicron variant surge M Abdelrahim, A Esmail, N Al Saadi, E Zsigmond, E Al Najjar, D Bugazia, ... Frontiers in Pharmacology 13, 848676, 2022 | 10 | 2022 |
| Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma GP Botta, M Abdelrahim, RL Drengler, VN Aushev, A Esmail, G Laliotis, ... The Oncologist, oyae155, 2024 | 8 | 2024 |
| Transplant oncology: An emerging discipline of cancer treatment M Abdelrahim, A Esmail, A Abudayyeh, N Murakami, D Victor, S Kodali, ... Cancers 15 (22), 5337, 2023 | 7 | 2023 |
| Immune checkpoint inhibitors for solid tumors in the adjuvant setting: current progress, future directions, and role in transplant oncology K Abboud, G Umoru, A Esmail, A Abudayyeh, N Murakami, HO Al-Shamsi, ... Cancers 15 (5), 1433, 2023 | 7 | 2023 |
| Early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma using circulating tumor DNA M Abdelrahim, A Esmail, J Xu, TA Katz, S Sharma, E Kalashnikova, ... Journal of Surgery and Research 4 (4), 602-615, 2021 | 5 | 2021 |
| Tyrosine kinase inhibitors (TKIs) plus transarterial chemoembolization (TACE) compared to TACE alone as downstaging therapy in transplant recipients with hepatocellular carcinoma A Esmail, S Kodali, E Graviss, D Nguyen, L Moore, A Saharia, A Uosef, ... Annals of Oncology 33, S308, 2022 | 4 | 2022 |
| Combination of gemcitabine plus cisplatin compared to non-gemcitabine and cisplatin regimens as neo-adjuvant treatment in liver transplant recipients with cholangiocarcinoma M Abdelrahim, A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia Annals of Oncology 33, S309-S310, 2022 | 4 | 2022 |
| Feasibility of gemcitabine plus cisplatin as neo-adjuvant in cholangiocarcinoma patients prior to liver transplantation A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia, M Abdelrahim Annals of Oncology 33, S310, 2022 | 4 | 2022 |
Maen AbdelrahimHouston Methodist Cancer CenterVerified email at houstonmethodist.org